Numab Therapeutics Taps Veteran Rajesh Chopra to Lead Clinical Immunology Push

HORGEN, Switzerland – October 01, 2026 — For decades, the biopharmaceutical industry’s approach to complex inflammatory diseases has resembled a game of biological whack-a-mole. Traditional single-target biologics suppress one inflammatory pathway, only for the disease to circumvent the blockade via another. Now, a new generation of multispecific antibodies is emerging, designed to strike multiple targets simultaneously. At the forefront of this shift is Numab Therapeutics, a clinical-stage Swiss biotechnology company that today announced a significant strategic move: the appointment of Dr. Rajesh Chopra as its new Chief Scientific Officer.

The hiring of Dr. Chopra, a veteran drug hunter with nearly forty years of experience across oncology, immunology, and translational medicine, signals a pivotal maturation phase for the Horgen-based firm. Known for its proprietary antibody discovery and engineering platforms—including its λ-Cap™, λ-Stealth™, and MATCH™ technologies—Numab is clearly transitioning its focus from platform validation to high-value clinical execution. By bringing in an executive with a track record spanning big pharma, venture capital, and biotech company creation, the company is positioning its proprietary pipeline, notably its lead trispecific antibody for inflammatory bowel disease (IBD), for the global stage.

The Evolution of a Drug Hunter

In the life sciences sector, a platform is only as valuable as the therapeutic candidates it yields. Translating elegant molecular engineering into tangible patient outcomes requires a specific, battle-tested expertise. Dr. Chopra brings exactly this pedigree to Numab.

His career is a masterclass in navigating the treacherous waters of drug development. Prior to joining Numab, Dr. Chopra served as Chief Scientific Officer at Prologue Medicines and spent several years as a Venture Partner and Head of Oncology at Apple Tree Partners. But his reputation was largely cemented during his tenures at pharmaceutical giants and leading research institutions. At Celgene, as Corporate Vice President of Translational and Early Drug Development, he shepherded numerous therapies from discovery through proof-of-concept, including foundational work on agents that would eventually gain regulatory approval for severe blood disorders.

Before his time in big pharma, Dr. Chopra directed the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) in London—an academic powerhouse that discovered 20 drugs in a single decade. He also co-founded Monte Rosa Therapeutics, a protein degradation company that successfully executed a $220 million initial public offering.

“Numab has built an exceptional scientific foundation, a differentiated technology platform and a pipeline with significant potential,” said Barbara Angehrn, Chief Executive Officer of Numab Therapeutics, in a statement regarding the appointment. “Raj brings deep expertise in translational medicine and drug development and a distinguished track record of advancing innovative therapies across oncology and immunology. His experience and leadership will be invaluable as we continue to advance our pipeline and scientific strategy. We are delighted to welcome him to Numab.”

The move to recruit an executive with such deep roots in both venture creation and clinical translation suggests that Numab is acutely aware of the challenges ahead. Moving complex biologicals through late-stage trials requires rigorous clinical strategy and the ability to articulate value to prospective partners and investors.

Trispecifics: A New Paradigm for Inflammatory Bowel Disease

The most pressing human need currently addressed by Numab’s pipeline is Inflammatory Bowel Disease (IBD), a debilitating condition affecting millions globally. For years, the gold standard of care has relied on single-target biologics, such as TNF inhibitors or anti-integrins. While these therapies have provided relief for many, a significant portion of patients either do not respond or eventually lose response over time. The underlying biology of IBD is simply too complex, driven by redundant and synergistic pathological mechanisms, for a single-target approach to be a universal cure.

Enter NM81, Numab’s lead proprietary program. NM81 is not just a standard monoclonal antibody; it is a trispecific antibody engineered to simultaneously engage three distinct targets. By modulating multiple disease-driving pathways at once, NM81 aims to provide a more comprehensive and durable therapeutic effect.

“What attracted me to Numab is the combination of a highly differentiated technology platform and a pipeline advancing toward important development milestones,” Dr. Chopra noted. “Numab’s approach to engineering multispecific antibodies addresses some of the key challenges in antibody drug development and provides a strong foundation for future innovation. With a promising lead program and opportunities to further expand the pipeline, this is an exciting time to join the company. I look forward to working with the talented team at Numab to advance innovative therapies for patients and help realize the full potential of the platform.”

The leap from bispecific to trispecific formats is technically daunting. It requires sophisticated molecular architecture to ensure the resulting molecule is stable, manufacturable, and behaves predictably within the human body. Numab’s proprietary MATCH platform, combined with advanced Fc engineering, is designed to reproducibly enable this modular design. If successful, NM81 could establish a new benchmark for efficacy in gastroenterology, offering hope to patients who have exhausted existing treatment options.

Balancing Alliances with Proprietary Ambition

Beyond the science, Dr. Chopra’s appointment highlights a fascinating corporate strategy common among successful European biotechnology firms: the delicate balance of high-profile pharmaceutical partnerships and proprietary asset maturation.

Historically, platform companies often license their technology early to generate non-dilutive capital. Numab has executed this playbook effectively, establishing strategic alliances with global players such as Ono Pharmaceutical, Boehringer Ingelheim, and Kaken. These partnerships validate the underlying engineering capabilities of the λ-Cap™ and MATCH™ technologies while providing the financial runway necessary to sustain operations.

However, the true value-inflection point for any biotech lies in wholly owned assets. By advancing NM81 and other internal programs in immunology and oncology, Numab is retaining the massive upside potential of its own discoveries.

Industry insiders note that bringing a heavyweight CSO on board is a classic precursor to scaling internal development. As one venture capital strategist observing the European biotech landscape remarked, transitioning a company from a partner-reliant discovery engine to an independent clinical powerhouse requires leadership that understands how to ruthlessly prioritize pipeline candidates. The right CSO doesn't just advance science; they kill doomed projects early and double down on the assets with the highest probability of clinical and commercial success.

The Road Ahead for Multispecific Modalities

The broader biopharmaceutical industry is currently witnessing a massive influx of capital into multispecific antibody formats. Major players like Roche, AbbVie, and Sanofi are heavily invested in next-generation biologics, particularly in the immunology space. Precision medicine is no longer confined to oncology; there is a growing mandate to bring fine-tuned, multi-targeted modulation to autoimmune and inflammatory conditions.

Numab’s ability to differentiate its trispecific approach will depend entirely on clinical data. The company must demonstrate that the added complexity of a trispecific molecule translates directly into superior safety and efficacy profiles compared to the emerging crop of bispecifics and next-generation oral therapies.

With Dr. Chopra at the scientific helm, Numab is fortifying its defenses against the inherent risks of drug development. His nearly forty years of experience—spanning the initial discovery of novel mechanisms to the regulatory approval of commercial therapies—provides the strategic oversight necessary to navigate the complex regulatory and clinical pathways ahead. As NM81 progresses through its clinical milestones, the industry will be watching closely to see if this Swiss innovator can successfully redefine the standard of care for complex inflammatory diseases, turning elegant molecular engineering into a tangible reality for patients.